All In Biotech

Drug Trial Radar · NCT01112306

ACT-293987 in Pulmonary Arterial Hypertension

Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of ACT-293987 in Patients With Pulmonary Arterial Hypertension

Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

709

Actual

Start

Jul 7, 2010

Primary completion

Aug 26, 2021

Study completion Aug 26, 2021

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 28, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • ACT-293987Drug

    Tablets, twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention DiscontinuationTime frame: Up to 3 days after study drug discontinuation (Up to 10.5 years)
  2. Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 3 Days After Study Intervention DiscontinuationTime frame: Up to 3 days after study drug discontinuation (Up to 10.5 years)
  3. Number of Participants With TEAEs Leading to Permanent Discontinuation of Study InterventionTime frame: Up to 10.5 years

Locations

157 sites in 38 countries. Site status is shown where the registry gives one.

  • Site not named

    Mobile, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    Torrance, California

  • Site not named

    Newark, Delaware

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Austell, Georgia

  • Site not named

    Carmel, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    Kansas City, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Troy, Michigan

  • Site not named

    Rochester, Minnesota

  • Site not named

    Chesterfield, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Newark, New Jersey

  • Site not named

    Islandia, New York

  • Site not named

    New York, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Bend, Oregon

  • Site not named

    Portland, Oregon

  • Site not named

    Doylestown, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    York, Pennsylvania

  • Site not named

    Nashville, Tennessee

  • Site not named

    Dallas, Texas

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.